Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced that it has been issued a trademark for RECCE^® by the Trade Marks Registry Intellectual Property Department in Hong Kong. This newly registered trademark strengthens the Company’s global intellectual property (IP) portfolio.

The Company has been issued Hong Kong Trademark No. 306020153 and has been classified under Class 5 for antibiotics, antibiotics for human use and pharmaceutical preparations, namely mixed antibiotic preparations.

“With patents in Hong Kong for RECCE^® anti-infectives in place out to 2037, we now celebrate further exclusivity through the trademark registration of RECCE^®,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

The pharmaceutical market in Hong Kong is valued at $2.3 billion, with rising demand for chronic disease treatment.¹ Data presented by the Hospital Authority of Hong Kong shows a proportionally high level of anti-microbial resistance in both Gram-positive and Gram-negative bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), Cephalosporin-resistant and Fluoroquinolone-resistant Escherichia coli, in Hong Kong relative to other countries.² 

RECCE^® is also registered in the biggest pharmaceutical markets in the world such as Australia, Europe, Japan, China and the U.S.